Vertex Pharmaceuticals Incorporated
http://www.vrtx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vertex Pharmaceuticals Incorporated
Stock Watch: Investor Reactions Diverge As J&J And Novartis Report Q2 Results
Both of the first two companies to report second-quarter financials maintained full-year sales guidance. But while Johnson & Johnson’s investors seemed cheered, Novartis’s may have been concerned about familiar issues.
Asia Deal Watch: Orum, Vertex Team Up On Gene Editing Conditioning Agents
Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.
Vertex Opens New Front In Patient Assistance Conflict Between Pharma, HHS Inspector General
Vertex’s fertility preservation assistance program would provide up to $70,000 in financial support for in vitro fertilization and other services to patients prescribed Casgevy.
Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications
Half of the FDA’s upcoming 2024 user fee goals target rare diseases, but highly prevalent conditions like uncomplicated urinary tract infections and atopic dermatitis are also up for agency action in the second half of the year.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- ViroChem Pharma Inc., Exonics Therapeutics, Inc., Semma Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice